Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Daniela, Katz"'
Autor:
Aryeh Babkoff, Yael Berner-Wygoda, Judith Diment, Anatoli Kustanovich, Aviad Zick, Daniela Katz, Albert Grinshpun
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 954-962 (2023)
Small round cell sarcoma is a group of undifferentiated malignancies arising in the bone and soft tissue, notable for Ewing sarcoma. Recently, a new World Health Organization classification has been introduced, including an additional subset of these
Externí odkaz:
https://doaj.org/article/7f9484d2f9f74aa49c8e9c43d0650ac9
Autor:
Ayelet Shapira-Daniels, MD, Daniela Katz, MD, Gal Aviel, MD, Amichay Meirovitz, MD, Dan Gilon, MD, Oz M. Shapira, MD
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 3, Pp 519-522 (2020)
Externí odkaz:
https://doaj.org/article/978e42ceb2ff4d08a530a21c51120777
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-3 (2018)
Abstract Background Pazopanib is a tyrosine kinase inhibitor indicated for the treatment of renal cell carcinoma and soft tissue sarcoma. Despite the high inter-patient variability in pharmacokinetic exposure, pazopanib is administered at a fixed dos
Externí odkaz:
https://doaj.org/article/615ef921eef54d52bfb368bab238f9c9
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0194409 (2018)
Screening mammograms are widely recommended biennially for women between the ages of 50 and 74. Despite the benefits of screening mammograms, full adherence to recommendations falls below 75% in most developed countries. Many studies have identified
Externí odkaz:
https://doaj.org/article/218cf226d7ba402b86f8c28ba49be5fc
Publikováno v:
Journal of Orthopaedic Surgery, Vol 25 (2017)
Background: Percutaneous radiofrequency ablation (RFA) has been shown to be an effective treatment for soft tissue lesions and also benign bone tumors, especially osteoid osteoma. There are limited data regarding this technique in other bone tumors,
Externí odkaz:
https://doaj.org/article/7b128937c0914fa3988e319b5f3f559d
Autor:
Bernd Kasper, Hans Gelderblom, Jenny Sherriff, Filomena Mazzeo, Francesco Tolomeo, Jean-Yves Blay, Florence Duffaud, Piotr Rutkowski, Lorenzo D'Ambrosio, Daniela Katz, Christine Chevreau, Giovanni Grignani, Isabelle Ray-Coquard, Anna M. Czarnecka, Sophie Piperno-Neumann, Ronan Flippot, Saskia Litière, Ward Sents, Axel Le Cesne, Roberta Sanfilippo, Dan Stark, Bruno Vincenzi, Alessandro Gronchi, Nathan Touati, Anna Estival, Silvia Stacchiotti, Armin Tuchscherer, Javier Martin-Broto
Publikováno v:
Cancer, 126(11), 2637-2647. WILEY
Cancer, Vol. 126, no.11, p. 2637-2647 (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Cancer, Vol. 126, no.11, p. 2637-2647 (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname
European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
[Background] The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype‐specific prospective controlled data lacking, this
[Background] The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype‐specific prospective controlled data lacking, this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abbd8840824675e8c9ac3e51a0a547f3
http://hdl.handle.net/2318/1869280
http://hdl.handle.net/2318/1869280
Publikováno v:
Oncotarget
Leiomyosarcoma is the second most frequent soft-tissue sarcoma. Tumor lymphocytic infiltration (TIL) and programed cell death ligand-1 (PD-L1) have been associated with prognosis in different malignancies while DNA mismatch-repair deficiency (MMR-D)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212823176b2e7d49aa04375944d0d8a1
https://doi.org/10.18632/oncotarget.25747
https://doi.org/10.18632/oncotarget.25747
Autor:
Shulamith Rizel, Michelle Leviov, Debbie M Jakubowski, David B. Geffen, Ora Rosengarten, Mariana Steiner, Steven Shak, Avital Bareket-Samish, Noa Ben-Baruch, Margarita Tokar, Amit Itay, Daniela Katz, Julie Baron, Nicky Liebermann, Salomon M. Stemmer, Lior Soussan-Gutman, Beatrice Uziely, Bella Nisenbaum, Georgeta Fried
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-6 (2019)
NPJ Breast Cancer
NPJ Breast Cancer
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4728233c9753d3200b2717aab0399ebf
https://doi.org/10.1038/s41523-019-0137-3
https://doi.org/10.1038/s41523-019-0137-3
Sarcomas are a diverse group of cancers with mesenchymal origin. Although sarcomas comprise less than 1% of cancers, there are more than 50 different subtypes that are quite different from one another in terms of both their biology and clinical behav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c383aa5c01d6f4349e57ade95582a4e
http://hdl.handle.net/11585/778960
http://hdl.handle.net/11585/778960
Autor:
Ofer Merimsky, Roberta Sanfilippo, Klaus Freivogel, Charlotte Benson, Giovanni Grignani, Ian Judson, Minesh Jobanputra, Dara Stein, Stephanie Manson, Hans Gelderblom, Daniela Katz, Arron Mungul
Publikováno v:
Acta Oncologica, 56(12), 1769-1775
Background: A named patient program (NPP) was designed to provide patients with advanced soft-tissue sarcoma (aSTS) access to pazopanib, a multitargeted tyrosine kinase inhibitor. The SPIRE study was a retrospective chart review of participating pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dacdd7d98d617b1db79183f56fe4d97
http://hdl.handle.net/1887/94732
http://hdl.handle.net/1887/94732